Dr. Amyn Habib is an Associate Professor in the Department of Neurology at UT Southwestern Medical Center, and a Staff Physician at the VA North Texas Health Care System/ Dallas VA Medical Center. As a physician scientist, Dr. Habib attends to patients with neurological disorders and also runs an active basic science research laboratory.

He received his medical degree from Dow Medical College in Karachi, Pakistan. He did his internship at Henry Ford Hospital in Detroit, followed by a Neurology Residency at the University of Chicago Medical Center.  He then undertook research fellowships at the University of Chicago and at Beth Israel Deaconess Medical Center/Harvard Medical School.  He was an Instructor of Neurology at Harvard Medical School prior to joining UT Southwestern.

His research interests include investigation of growth factor signaling pathways in glioblastoma and other cancers. His work has elucidated the interaction between normal and mutant epidermal growth factor receptors (EGFR) in glioblastoma.  In addition, his laboratory has identified and characterized interactions between inflammatory and oncogenic signaling pathways in cancer.  His laboratory has provided a fundamental insight in the biology of EGFR signaling by demonstrating that constitutive and ligand-induced EGFR signaling triggers distinct and mutually exclusive downstream signaling networks.   More recent work in his laboratory has focused on mechanisms of resistance to targeted treatment in cancer with a particular focus on glioblastoma and lung cancer and identified therapeutic approaches to overcome the resistance of glioblastoma and non-small cell lung cancer (NSCLC) to EGFR inhibition.   Additional areas of active interest in the laboratory include mechanisms that regulate the invasion and proliferation of tumor cells in glioblastoma.  His research is funded by the NIH and by the Department of Veteran’s Affairs.


Medical School
Dow Medical College - Pakistan (1986), Medicine

Research Interest

  • Mechanisms of resistance to targeted treatment in cancer
  • Molecular Mechanisms regulating glioblastoma invasion and proliferation
  • The role of inflammation in gliomagenesis


Featured Publications LegendFeatured Publications

An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases.
Liu Y, Crowe WN, Wang L, Lu Y, Petty WJ, Habib AA, Zhao D, Nat Commun 2019 Nov 10 1 5108
Radiation-induced DNA damage cooperates with heterozygosity of TP53 and PTEN to generate high grade gliomas.
Todorova PK, Fletcher-Sananikone E, Mukherjee B, Kollipara R, Vemireddy V, Xie XJ, Guida PM, Story MD, Hatanpaa K, Habib AA, Kittler R, Bachoo R, Hromas R, Floyd JR, Burma S, Cancer Res. 2019 May
MRI Evaluation of the effects of Whole Brain Radiotherapy on Breast Cancer Brain Metastasis.
Crowe W, Wang L, Zhang Z, Varagic J, Bourland JD, Chan MD, Habib AA, Zhao D Int. J. Radiat. Biol. 2018 Nov 1-27
Genetic and Epigenetic Features of Rapidly Progressing IDH-Mutant Astrocytomas.
Richardson TE, Sathe AA, Kanchwala M, Jia G, Habib AA, Xiao G, Snuderl M, Xing C, Hatanpaa KJ J. Neuropathol. Exp. Neurol. 2018 May

Honors & Awards

  • Clinical Investigator Award
    National Cancer Institute (1999)